Información del producto
- (3S,4S)-4-[(3,4-Dimethoxyphenyl)methyl]-3-[[4-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-3-hydroxy-2(3H)-furanone
- 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)-3-((4-(beta-D-glucopyranosyloxy)-3-methoxyphenyl)methyl)dihydro-3-hydroxy-, (3S-cis)-
- 2(3H)-Furanone, 4-[(3,4-dimethoxyphenyl)methyl]-3-[[4-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-3-hydroxy-, (3S,4S)-
- 2(3H)-Furanone, 4-[(3,4-dimethoxyphenyl)methyl]-3-[[4-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-3-hydroxy-, (3S-cis)-
- 2-Hydroxyarctiin
- 8′-Hydroxyarctigenin-4′-O-β-<span class="text-smallcaps">D</span>-glucoside
Tracheloside significantly decreases the activity of alkaline phosphatase (AP), an estrogen-inducible marker enzyme, with an IC(50) value of 0.31 microg/ml, a level of inhibition comparable to that of tamoxifen (IC(50) = 0.43 microg/ml).
Propiedades químicas
Consulta técnica sobre: BP-BP1401 Tracheloside
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.